East Money· 东方财富网·· 17 hours agoPickScore63
ARO-MAPT Phase 1/2a Interim Data: Subcutaneous siRNA Delivers Deep CSF Tau Reductions in Healthy Volunteers
In brief
On October 14, Arrowhead reported interim Phase 1/2a data for ARO-MAPT: in healthy volunteers, CSF total Tau protein fell by an average of 40%–73% (maximum 85%) at day 105 after subcutaneous dosing. Day 105 was 90 days after the last dose, supporting dosing every three months or less frequently.
Why it matters
Subcutaneous ARO-MAPT achieved marked Tau knockdown in healthy volunteers, adding human dose-response data for CNS oligonucleotide delivery.
Source: East Money · data.eastmoney.com